As consumers, legislators, and doctors learn more about the tremendous health benefits of cannabis-related treatments, cannabis companies like Earth Science Tech (OTC:ETST), Axim Biotechnologies (OTC: AXIM), and GW Pharma (NASDAQ: GWPH) stand to directly benefit from an increasing total attainable market. Recent shifts in policy at the state-level in over half of the U.S. states have spurred tremendous revenue growth and investments in the cannabis industry, with Axim receiving over $150M in investment from one firm alone.

Earth Science Tech, Inc. (OTC: ETST) has focused on two main segments: medical devices and CBD treatments. The company recently announced its plans to begin distributing its MSN-2 medical devices in several countries across the globe, and they teased that they will be working closely with legislators and distributors in these countries to build strong, mutually beneficial relationships. As CBD-based treatments gain more traction, these newly formed relationships could help ETST create a strong, global market for its CBD products, which it recently announced a new branding and marketing initiative for. This leads to another point that ETST recently brought up: clinical studies. The company is ramping up for human clinical trials for CBD products in the upcoming year, which will be used to better understand, develop, and market new CBD-based treatment options for a variety of ailments, including HIV and neurological disorders.

Axim and GW Pharma are also both heavily focused on research and development goals for 2018. Axim is developing a new CBD-infused chewing gum, which it will market to patients with restless leg syndrome. GW Pharma has positioned its patent portfolio very well, receiving orphan designations for a number of its drugs. GW Pharma announced that it is actively developing a dozen new cannabinoid-based treatments, and the company has stated that they believe 2018 will be their breakout year.

With the rapid sector growth and positively turning political tides, it could stand to reason that 2018 will be a breakout year for not only GWPH, but AXIM, ETST, and a number of other key market players with innovative CBD treatments under development.